After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NASDAQ listed company, MRUS falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Merus N.V is $4.98B. A total of 0.63 million shares were traded on the day, compared to an average of 1.15M shares.
In the most recent transaction, Silverman Peter B. sold 25,000 shares of MRUS for 60.00 per share on Jul 17 ’25. After the transaction, the COO & GC now owns 0 company shares. In a previous transaction on Jul 17 ’25, Silverman Peter B. bought 25,000 shares at 60.00 per share.
Among the insiders who sold shares, Silverman Peter B. disposed of 16,805 shares on Jul 10 ’25 at a per-share price of $55.00. This resulted in the COO & GC holding 0 shares of MRUS after the transaction. In another insider transaction, Silverman Peter B. sold 6,695 shares at $55.00 per share on Jul 09 ’25. Company shares held by the COO & GC now total 0.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, MRUS has a high of $66.43 and a low of $33.19.
As of this writing, MRUS has an earnings estimate of -$1.15 per share for the current quarter. EPS was calculated based on a consensus of 14.0 estimates, with a high estimate of -$0.93 per share and a lower estimate of -$1.49.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. MRUS’s latest balance sheet shows that the firm has $410.43M in Cash & Short Term Investments as of fiscal 2021. There were $3.75M in debt and $71.90M in liabilities at the time. Its Book Value Per Share was $8.62, while its Total Shareholder’s Equity was $316.20M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for MRUS is Buy with a score of 4.94.
